Sequencing-Based Tropism Testing for HIV May Be Feasible, if Not Yet Commercially Viable
May 24, 2011
Sequencing-Based Tropism Testing for HIV May Be Feasible, if Not Yet Commercially Viable
Testing the ability of Roche's 454 GS FLX to detect viral tropism, researchers sequenced the viruses of 14 HIV patients, selecting specifically for the V3 loop of the virus, the region that allows it to infect human immune cells.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Study Finds Roche's NGS-Based HIV Assay Comparable to TruGene; Company Expects 2014 CE-IVD Approval
January 30, 2013 / Clinical Sequencing News - Pathogenica Plans 2012 Launch for Sequencing-Based HPV Dx; HIV and HCV Tests in Pipeline
August 17, 2011 / Clinical Sequencing News - Q&A: Pfizer's Dominic Spinella on the Challenges of Using NGS in Clinical Trials
June 21, 2011 / Clinical Sequencing News - Exome Sequencing IDs Druggable BRAF Mutation in 47 HCL Patients
June 15, 2011 / Clinical Sequencing News - HudsonAlpha Researchers to Sequence Immune Repertoires of 10K Individuals for 100 Diseases
May 24, 2011 / Clinical Sequencing News